

Immune Checkpoint Inhibitors Market - 2023-2031

<https://marketpublishers.com/r/IBE2FCE1DD57EN.html>

Date: February 2025

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: IBE2FCE1DD57EN

Abstracts

The Immune Checkpoint Inhibitors Market was valued at US\$ 40.1 billion in 2023 and is anticipated to reach US\$ 156.6 billion by 2031, at a CAGR of 0.165 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Immune Checkpoint Inhibitors Market.

This report delivers a comprehensive overview of the Immune Checkpoint Inhibitors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Immune Checkpoint Inhibitors Market. The Immune Checkpoint Inhibitors Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Immune Checkpoint Inhibitors Market Scope:

By Type

PD-1 Inhibitors

PD-L1 Inhibitors

CTLA-4 Inhibitors

LAG-3 Inhibitors (Relatlimab)

Others

By Application

Breast Cancer

Bladder Cancer

Cervical Cancer

Colon Cancer

Hodgkin Lymphoma

Liver Cancer

Lung Cancer

Others

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Key Players

Bristol-Myers Squibb Company.

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd

AstraZeneca

Regeneron Pharmaceuticals, Inc.

Eli Lilly and Company

BeiGene LTD.

GSK plc

Coherus BioSciences, Inc.

Incyte.

Major Highlights

This report delivers a comprehensive overview of the Immune Checkpoint Inhibitors Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Immune Checkpoint Inhibitors Market. The Immune Checkpoint Inhibitors Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the

latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Application
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Incidence of Cancer
 - 4.1.1.2. XX
 - 4.1.2. Restraints
 - 4.1.2.1. High Cost of Treatments
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis

6. BY TYPE

- 6.1. Introduction
 - 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
 - 6.1.2. Market Attractiveness Index, By Type

- 6.2. PD-1 Inhibitors *
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 6.2.3. Pembrolizumab
 - 6.2.4. Nivolumab
 - 6.2.5. Cemiplimab
- 6.3. PD-L1 Inhibitors
 - 6.3.1. Atezolizumab
 - 6.3.2. Avelumab
 - 6.3.3. Durvalumab
- 6.4. CTLA-4 Inhibitors
 - 6.4.1. Ipilimumab
 - 6.4.2. Tremelimumab
- 6.5. LAG-3 Inhibitors (Relatlimab)
- 6.6. Others

7. BY APPLICATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 7.1.2. Market Attractiveness Index, By Application
- 7.2. Breast Cancer *
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Bladder Cancer
- 7.4. Cervical Cancer
- 7.5. Colon Cancer
- 7.6. Hodgkin Lymphoma
- 7.7. Liver Cancer
- 7.8. Lung Cancer
- 7.9. Others

8. BY DISTRIBUTION CHANNEL

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Hospital Pharmacies *
 - 8.2.1. Introduction

- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Retail Pharmacies
- 8.4. Online Pharmacies

9. BY REGION

9.1. Introduction

- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region

9.2. North America

- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.2.6.1. U.S.
 - 9.2.6.2. Canada
 - 9.2.6.3. Mexico

9.3. Europe

- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.3.6.1. Germany
 - 9.3.6.2. U.K.
 - 9.3.6.3. France
 - 9.3.6.4. Spain
 - 9.3.6.5. Italy
 - 9.3.6.6. Rest of Europe

9.4. South America

- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 9.4.6.1. Brazil
- 9.4.6.2. Argentina
- 9.4.6.3. Rest of South America

9.5. Asia-Pacific

- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.5.6.1. China
 - 9.5.6.2. India
 - 9.5.6.3. Japan
 - 9.5.6.4. South Korea
 - 9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE

- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

- 11.1. Bristol-Myers Squibb Company. *
 - 11.1.1. Company Overview
 - 11.1.2. Product Portfolio and Description
 - 11.1.3. Financial Overview
 - 11.1.4. Key Developments
- 11.2. Merck & Co., Inc.
- 11.3. F. Hoffmann-La Roche Ltd
- 11.4. AstraZeneca
- 11.5. Regeneron Pharmaceuticals, Inc.

- 11.6. Eli Lilly and Company
- 11.7. BeiGene LTD.
- 11.8. GSK plc
- 11.9. Coherus BioSciences, Inc.
- 11.10. Incyte. (*LIST NOT EXHAUSTIVE)

12. APPENDIX

- 12.1. About Us and Services
- 12.2. Contact Us

I would like to order

Product name: Immune Checkpoint Inhibitors Market - 2023-2031

Product link: <https://marketpublishers.com/r/IBE2FCE1DD57EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IBE2FCE1DD57EN.html>